ClinBrain Secures Hundred-Million-Yuan Series B Funding to Accelerate Medical Big Data Technology Development
Recently, VCBeat (WeChat ID: vcbeat) learned at the earliest opportunity thatMedical Big Data Company ClinBrain Completes RMB 100 Million+ Series B Financing Round, Led by Zhilin Capital with Participation from Qianhai Fund of Funds, Mifang Capital, and Langcheng Capital; Existing Shareholder Guangrun Capital Continues to Follow On
ClinBrain, established in 2013, is a medical big data company headquartered in Shanghai. The company currently holds 71 software copyrights related to medical big data and has filed 17 invention patents in this field.
In a challenging economic environment, investors’ decision to back ClinBrain not only reflects strong recognition of the company’s current development but also solidifies its competitive advantage for sustained growth in the medical big data sector.
When discussing investment logic,Jiang Haotian, Founder of Zhilin Capital, the lead investor in this round, stated:
Public hospitals have served as the primary battleground for digital transformation in the healthcare industry, making significant progress over the years. However, the various hospital information systems, developed through incremental investments over time, remain unintegrated, resulting in data silos that hinder both internal clinical research and external connectivity. In the post-pandemic era, national policies have greatly accelerated the pace of healthcare digitization, prompting hospitals to recognize the critical importance and urgency of establishing “data middle platforms” and “business middle platforms.” As a leading enterprise in the field of medical big data technology, ClinBrain is poised to seize this opportunity for accelerated growth. We hold strong confidence in ClinBrain’s team and its high market recognition, and we are highly optimistic about its potential to unlock and leverage the value of medical data in the future.
It is reported that,Following the completion of this round of financing, ClinBrain will further increase its R&D investment, strengthen the teams responsible for medical big data product development and engineering delivery, advance the nationwide market deployment and overall strategic upgrade of its medical big data middle platform, and continue to deepen its expertise in the medical big data sector.
Driven by the General Office of the State Council’s 2016 release of the “Guiding Opinions on Promoting and Standardizing the Application and Development of Health and Medical Big Data,” as well as subsequent policies issued by the National Health Commission, including the “Administrative Measures and Evaluation Standards for Graded Assessment of Electronic Medical Record System Application Levels” and the “Evaluation Scheme for Standardization Maturity of Hospital Information Interconnectivity,” China’s healthcare informatization has achieved rapid development. ClinBrain, specializing in the integration, governance, application, and services of medical big data, is a key player advancing amidst this opportunity.
ClinBrain has been in operation for over seven years. Since its inception in 2013, the company adopted the name “ClinBrain,” embodying the concept of a “Clinical Brain,” and positioned itself in the governance, mining, and application of medical big data, providing intelligent dataset support to the healthcare industry. Years later, ClinBrain remains committed to its original mission and continues to move forward. The company’s founders bring nearly two decades of experience in the healthcare sector, endowing the enterprise with strong capabilities in product research and development as well as marketing.
In addition to its deep commitment to product development, ClinBrain has also established a robust product pipeline in the field of medical big data.
ClinBrain’s products consist of three components: ClinData, ClinAPP, and ClinAI.
One is the “ClinData” series of data middle platforms and data governance products, centered on the Clinical Data Repository (CDR), Operational Data Repository (ODR), Research Data Repository (RDR), intelligent healthcare data ETL, healthcare metadata management, healthcare master data management, and healthcare data quality management;
The second category comprises the “ClinAPP” series of medical data applications and business integration products, represented by the clinical big data search engine, the clinical research platform for single-disease and cohort studies, the medical big data statistical mining platform, medical big data visualization, hospital operational management, medical quality management, Patient 360, Caregiver 360, and the Health Service Bus (HSB) information integration platform.
Third, the “ClinAI” series of intelligent healthcare products, represented by natural language processing (NLP), intelligent structuring of medical record data, pathological data, and imaging report data, intelligent interpretation of medical literature and clinical guidelines, and an intelligent early-warning platform for COVID-19 infection.
Meanwhile, ClinBrain has engaged in collaborative initiatives and practical applications with major Grade-A tertiary hospitals, including West China Hospital, Ruijin Hospital, and Changhai Hospital, to gain an in-depth understanding of hospital needs and use these insights as a benchmark for continuous product research and development.
With the advancement of healthcare informatization, massive amounts of data have accumulated; however, gaps in medical data management capabilities remain unaddressed. The imbalance between “massive data” and “healthcare challenges” requires the construction of a “bridge” in the form of big data governance in healthcare. ClinBrain has been continuously exploring solutions along this demand trajectory, building a robust product pipeline grounded in deep industry understanding, and steadily advancing its “productization” and “intelligentization.”
In 2015, ClinBrain attracted the attention of the Shanghai Municipal Health and Family Planning Commission and participated as a key architectural design entity in the compilation of Construction and Practice of Hospital Information Integration Platform in Shanghai, edited by the Information Center of the Shanghai Municipal Health and Family Planning Commission.
Furthermore, ClinBrain served as an editorial board member for the Guidelines for the Construction of Clinical Data Retrieval Systems in Traditional Chinese Medicine Hospitals and the Guidelines for the Construction of a Shared Database of Typical Cases from Renowned Veteran TCM Practitioners, and participated in the development of medical data standards such as the Specifications for the Construction of Medical Data Centers in Guangdong Province and the Basic Research Dataset for Patients with Novel Coronavirus Pneumonia.
Over the years of development in the medical big data industry, ClinBrain has accumulated rich resources. ItsMedical Big Data UsersCurrently, coverage extends to more than ten provinces, autonomous regions, and municipalities directly under the Central Government, including Shanghai, Sichuan, Guangdong, Shandong, Zhejiang, Jiangsu, and Chongqing. Major general Grade 3A hospital clients include West China Hospital, Ruijin Hospital, Changhai Hospital, the First Affiliated Hospital of Xi’an Jiaotong University, the People’s Hospital of Guangxi Zhuang Autonomous Region, the Second Affiliated Hospital of Wenzhou Medical University, and Foshan First People’s Hospital. Collaborations have also been established with numerous Grade 3A specialized hospitals in oncology, maternal and child health, psychiatry, and traditional Chinese medicine.
AsLiu Huanchun, Founder of ClinBrainAs stated: “Only when data is truly utilized will hospitals regard it as an asset, akin to purchased medical equipment and devices. When data cannot be effectively leveraged, its value remains unrealized. ClinBrain helps hospitals build big healthcare data assets, creating value for hospitals while serving public health.”
Qin Xiaohong, Co-founder of ClinBrainHe stated, “For years, medical data has been scattered across dozens or even hundreds of operational systems. Due to factors such as heterogeneous sources, disparate structures, and inconsistent standards, the data has become dirty, disorganized, and poor in quality. ClinBrain takes medical data governance as its core mission, helping hospitals build high-quality medical big data. Leveraging this big data, we support a wide range of clinical, research, and management applications, thereby continuously creating value for hospitals.”
ClinBrain’s deep commitment to the field of healthcare big data reflects its steadfast principles. Looking ahead, the company will continue to focus on healthcare big data, leveraging a philosophy of continuous innovation to advance the application of medical data and provide intelligent data support to the healthcare industry.
ZhiLin Capital, founded by Mr. Jiang Haotian, former Senior Partner at Northern Light Venture Capital, is a venture capital fund focused on industrial digital transformation and hard-tech innovations within the TMT sector. ZhiLin Capital is committed to investing in technology-driven enterprises, closely tracking emerging growth points related to digital technologies across various industries. It strives to provide premium support to high-caliber entrepreneurs, aiming to jointly create the greatest possible long-term success.
Qianhai Fund of Funds was officially established in January 2016. Led by Jin Haitao, a pioneering figure in China’s venture capital industry, its management team comprises partners from top-tier investment institutions, each boasting an average of over 20 years of investment management experience. It is currently the largest commercially raised fund of funds in China, as well as the single largest venture capital and private equity fund in terms of capital raised domestically, with a total committed capital of RMB 28.5 billion to date.
Mifang Capital is a professional investment fund in China focused on the pharmaceutical, healthcare, and life sciences sectors. Its fund management team possesses deep industry expertise in pharmaceuticals and healthcare, along with extensive venture capital experience. Mifang Capital has completed investments in approximately forty emerging companies, including TianGuangShi BioTherapeutics, Hanyu Medical, Zhanrong Pharma, Quest Diagnostics (QiuZhen Medicine), Lingke Pharmaceutical, Ansong Technology, Jiajian Medical, Weimi Biology, and Saifu Pharma. Adhering to the philosophy of “focusing on pharmaceutical, healthcare, and life sciences, leveraging capital value, and rewarding trust,” Mifang Capital is committed to becoming an open, platform-oriented professional pharmaceutical investment fund with prominent international competitiveness and far-reaching reputation.
Longcheng Capital, established in 2005, is one of the first domestic professional private equity firms specializing in brand investments in China. The company has consistently adhered to its professional investment philosophy of “Investment + Services,” focusing on equity investments in growing small and medium-sized private enterprises in China. Since its inception, Longcheng Capital has managed over ten funds, including the Zichen Investment Fund, and has established more than ten project-specific limited partnerships.
Langcheng Capital focuses on growth-stage and mature-stage investments, specializing in the intelligent manufacturing and healthcare sectors, while also covering new materials, new energy, and environmental protection industries. Its early-stage investment strategy centers on the “ABCII” domains: Artificial Intelligence, Big Data, Cloud Computing, Semiconductors, and the Internet of Things. Langcheng Capital is renowned among domestic equity investment firms for its high investment success rate. To date, 12 portfolio companies have achieved exit through initial public offerings (IPOs), and four have exited via mergers and acquisitions by listed companies, placing Langcheng Capital among the private equity fund managers with the highest project success rates for domestic equity investments in China.